Evidence map›Paper›PMID 32123197›Full record

Trial reportScientific reports2020

fMRI Revealed Reduced Amygdala Activation after Nx4 in Mildly to Moderately Stressed Healthy Volunteers in a Randomized, Placebo-Controlled, Cross-Over Trial.

Luisa Herrmann, Petya Vicheva, Vanessa Kasties, Lena V Danyeli, Gregor R Szycik, Dominik Denzel, Yan Fan, Johan Van der Meer, Johannes C Vester, Herbert Eskoetter and 2 more

2 registry-linked trialsAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02602275 phase2completednot on this map

Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands - A Randomized, Placebo-controlled, Double-blind, Cross-over Trial of Mode of Action and Response Prediction by Functional Magnetic Resonance Imaging MRI

TypeinterventionalSponsorBiologische Heilmittel Heel GmbHRan2015 to 2015Enrolled53ConditionsAcute Stress ReactionArmsNeurexan, Placebo
NCT06278077 phase2completednot on this mapstarted 2023, after this paper: background citation

Evaluation of the Effects of Neurexan® on Short-Term Insomnia, Daytime Performance and Stress Response by Polysomnography (PSG), Electroencephalogram (EEG), Stress Biomarkers and Patient-Reported Outcomes (PROs)

TypeinterventionalSponsorBiologische Heilmittel Heel GmbHRan2023 to 2026Enrolled81ConditionsInsomnia, Stress ReactionArmsNeurexan, Placebo
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Intrinsic Neural Timescales Relate to Event-Related Activity-Key Role for Intracolumnar Connections.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Luisa HerrmannDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, 72076, Germany.
Petya VichevaClinical Affective Neuroimaging Laboratory (CANLAB), Magdeburg, 39120, Germany.
Vanessa KastiesDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, 72076, Germany.
Lena V DanyeliDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, 72076, Germany.
Gregor R SzycikDepartment of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hanover, 30625, Germany.
Dominik DenzelClinical Affective Neuroimaging Laboratory (CANLAB), Magdeburg, 39120, Germany.
Yan FanDepartment of Psychiatry, Charité-CBF, Berlin, 12203, Germany.ORCID http://orcid.org/0000-0002-4864-859X
Johan Van der MeerQIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.
Johannes C Vesteridv Data Analysis and Study Planning, Krailling, 82152, Germany.
Herbert EskoetterMedical Consultant, Cologne, 50737, Germany.
Myron SchultzHeel GmbH, Baden-Baden, 76532, Germany.
Martin WalterDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, 72076, Germany. martin.walter@med.ovgu.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Social stress contributes to major societal health burdens, such as anxiety disorders and nervousness. Nx4 has been found to modulate stress responses. We investigated whether dampening of such responses is associated with neuronal correlates in brain regions involved in stress and anxiety. In a randomized, placebo-controlled, double-blind, cross-over trial, 39 healthy males took a single dose (three tablets) of either placebo or Nx4, 40 to 60 minutes before an fMRI scan session. We here report on drug effects on amygdala responses during a face-matching task, which was performed during a complex test battery further including resting-state brain connectivity and a social stress experiment. The first of the Primary Outcomes, defined in a hierarchical order, concerned reduced amygdala effects after intake of verum compared to placebo. We found a statistically significant reduction in differential activations in the left amygdala for the contrast negative faces versus forms during verum versus placebo condition. Our results indicate that effects of Nx4 can be monitored in the brain. Previously noted effects on stress responses may thus be modulated by affective brain regions including the amygdala.

Indexed as

Healthy VolunteersInterpersonal RelationsMagnetic Resonance ImagingAdultAmygdalaCross-Over StudiesDouble-Blind MethodFemaleHumansMalePlant ExtractsStress, PsychologicalneurexanPlant Extracts

Identifiers

PMID32123197
PMCPMC7052227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.